周五，H.C. Wainwright维持对Astria Therapeutics (NASDAQ:ATXS)的买入评级，目标价格坚持在16.00美元。该公司的关注点集中在本周早些时候关于一种竞争性特应性皮炎(AD)治疗方法的最新进展上。安进公司宣布了其OX40抗体rocatinlimab在HORIZON试验中的初步第三期结果。 研究报告显示，rocatinlimab的表现优于安慰剂，达到了所有主要 ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

特应性皮炎是最常见的湿疹类型，是一种慢性炎症性疾病，会导致皮肤过度干燥、瘙痒并伴有疼痛。中度至重度特应性皮炎患者会出现慢性症状，不可预测的发作会加剧症状，可能带来疼痛并扰乱日常生活。这些患者中几乎有一半报告出现严重瘙痒，导致反复抓挠，这会导致皮肤增厚 ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen's shares fell over 5% after updates on its Phase III immunology drug, rocatinlimab, raised investor concerns. While the ...

Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...

Amgen Inc.'s stock was down 4% Wednesday, after the company offered an update on two drugs in development, but analysts said neither look as effective as rival products from competitors.

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results ...

周三，Truist Securities维持对Amgen (NASDAQ:AMGN)股票的买入评级，目标价保持在320.00美元不变。这一决定是在Amgen披露两个主要管线项目的积极Phase 3更新之后做出的。这些项目涉及用于治疗全身性重症肌无力(gMG)的Uplizna，以及用于治疗特应性皮炎的rocatinlimab，后者是ROCKET项目在该适应症上的首次结果。 Amgen于周二报告了这些 ...

Leerink Partners analyst David Risinger has maintained their neutral stance on AMGN stock, giving a Hold rating today. David Risinger has ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...